No impact on blood sugar or insulin sensitivity One of the primary concerns with growth hormone use is its diabetogenic effect
Research status SLU-PP-332 is not FDA approved, has no established human dosage, and lacks a defined human safety profile
This precise mode of action may attract more consumers
This formula combines three highly recognized research peptides into a single product, making it a convenient option for laboratories investigating growth hormone signaling pathways, recovery mechanisms, and body composition-related biological processes
Special Precautions
Liver Health and Anti-Steatosis Activity: Reverses diet-induced hepatic steatosis by normalizing liver fat content to lean control levels, reduces liver adiposity by over 45%, improves hepatic metabolic profiles, and shifts lipid metabolism away from de novo synthesis toward enhanced fatty acid oxidation 2